Committee Connection
  • Induction Chemotherapy for Patients with Locally Advanced Head and Neck Cancer: To Induce or Not To Induce?

    24 Oct 2014 10:49 AM

    Introduction   Barbara Burtness, MDYale University School of MedicineThe role of induction chemotherapy in managing locally advanced head and neck cancer has been under exploration—and under debate—for three decades. The rationale for increasing exposure to systemic therapy has been expounded, and hints have been extrapolated from meta-analysis, or from trials comparing various induction regimens with each other, but not with... Read more

  • Robot-Assisted versus Open Radical Prostatectomy: Costs and Benefits

    26 Aug 2014 01:21 PM

    Introduction    By L. Michael Glodé, MD, FACP, FASCO University of Colorado Cancer Center The following articles by Dr. Quoc-Dien Trinh and Dr. Joel Nelson nicely review the current status of prostate cancer surgery and provide a framework within which one can discuss the approaches to definitive surgical ablation of the prostate. Although cost considerations should have been a part of the equation before dissemination of... Read more

  • Best Indications for PET/CT versus Contrast-Enhanced CT

    19 Jun 2014 02:37 PM

    Introduction   By Al B. Benson III, MD, FACP, FASCO Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University There is little question that advances in imaging technology have revolutionized cancer medicine, greatly enhancing precision in screening, diagnosis and staging, treatment, and surveillance. Functional imaging has the potential to refine staging accuracy and to provide a biologic... Read more

  • Cost of Cancer Care: A Crucial Physician-Patient Conversation

    22 Apr 2014 01:20 PM

    Introduction  Al B. Benson III,MD, FACP, FASCO By Al B. Benson III, MD, FACP, FASCOFeinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern UniversityCancer care costs and value are terms intertwined in the lexicon of the oncology discussion that has become the focal point of cancer care delivery over the past few years. Increasingly, clinicians and advocates alike... Read more

  • Neoadjuvant Therapy for Resectable Pancreatic Cancer

    25 Feb 2014 08:05 PM

    Introduction     By Sabha Ganai, MD, PhD Southern Illinois University School of Medicine Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, with five-year survival rates for patients with localized disease remaining under 25%.1 Despite improvements in morbidity and mortality from pancreas surgery, as well as a greater focus on preoperative imaging and staging prior... Read more

  • Immunotherapy for Prostate Cancer: Past, Present, and Future

    16 Dec 2013 04:27 PM

    By L. Michael Glodé, MD, FASCO University of Colorado, Denver   The field of immunotherapy for cancer has a long and complex history. Although there are reports of a relationship between infection and tumor regression dating to the 18th century, William Coley, MD, is often credited with being the “father of immunotherapy.” Ultimately, as head of the Bone Tumor Service at Memorial Hospital in New York, he injected over one... Read more